Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Staphylococcus aureus-induced septic arthritis of the ankle related to malum perforans in a diabetes patient.
Rom J Morphol Embryol
January 2022
Department of Immunology, Department of Biostatistics, University of Medicine and Pharmacy of Craiova, Romania;
Septic arthritis (SA) is a less common joint pathology with potentially fatal outcome. It is considered a medical emergency, in which prompt diagnosis and differentiation of bacterial etiology is essential for appropriate management. The knee is the most prevalent site for SA (~50% of cases), followed by hip, shoulder, and elbow.
View Article and Find Full Text PDFNecrotizing Fasciitis in a Patient on Long-Term Intramuscular Interferon-Beta for Multiple Sclerosis: A Case Report.
JBJS Case Connect
January 2021
Department of Critical Care and Trauma Surgery, Medstar Washington Hospital Center, Washington, DC.
Case: Immunomodulatory injections are becoming common long-term treatments for neuromuscular diseases such as multiple sclerosis (MS), although they carry a risk of local site infection. We describe a case of a 57-year-old man who developed necrotizing fasciitis of the anterior thigh secondary to intramuscular (IM) injections of interferon-beta-1A for MS, ultimately developing septic shock and requiring serial debridements for source control.
Conclusions: This is the first reported case of necrotizing fasciitis from chronic IM injections for MS and deserves particular attention because of the immunosuppressive nature of the injections.
Septic Arthritis Caused by Mycobacterium Kansasii in a Bone Marrow Transplant Recipient.
J Pediatr Hematol Oncol
November 2020
Departments of Pediatrics.
We report an 18-year-old female individual with septic arthritis due to Mycobacterium kansasii. Three years and 6 months before arthritis, the patient underwent bone marrow transplantation and developed severe chronic graft-versus-host disease. The arthritis was refractory to medication, and she underwent joint lavage of the right foot, hip joint, and elbow joint.
View Article and Find Full Text PDFAdverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.
BMC Res Notes
August 2019
Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Post Office Box 1400, 5021, Bergen, Norway.
Article Synopsis
- - The study aims to systematically analyze fatal adverse events linked to the treatment of multiple sclerosis with alemtuzumab (Lemtrada®) by reviewing data from the European Medicines Agency database.
- - Out of the ten cases reviewed, there were nine with probable and one with possible links to fatal outcomes, with most deaths occurring within the first month post-treatment due to various serious health issues.
- - The findings suggest fatal events related to alemtuzumab are more common than previously reported, emphasizing the need for increased awareness and monitoring during and after treatment.
Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Mult Scler Relat Disord
July 2018
1st Department of Internal Medicine, National and Kapodistrian University of Athens, University General Hospital "LAIKO", Greece. Electronic address:
A 47-year-old Caucasian female with relapsing- remitting Multiple Sclerosis, received alemtuzumab after a serious relapse. She had ceased receiving any treatment during the previous year. 23 days after alemtuzumab infusion she developed severe early neutropenia, which resulted in septic shock by Staphylococcus aureus and death.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!